- 4 hrs ago How Does The Body Convert Carbohydrates Into Energy?
- 5 hrs ago Actress Elli AvrRam Shares Some Intriguing Personal Experiences On Her TedXBITS Talk
- 6 hrs ago Is There A Link Between Drinking Too Much Water And Blood Pressure?
- 8 hrs ago Kottiyoor Utsavam 2022: Date, Time, History And Significance
- Movies Krushna Abhishek Reveals He Went Into Depression After His Debut Film’s Failure
- News Video: Portion of mountain crashes near J&K tunnel collapse site in Ramban
- Finance Ujjivan SFB Modifies Interest Rates On Saving Account Deposits: Check Rates Here
- Technology Snapdragon 8+ Gen 1 SoC Benchmarked: Better Than A15 Bionic
- Automobiles BMW M4 CSL Revealed With 542bhp - Ultralight M4 Drops 100 Kilos, Gains Iconic Badge
- Sports MS Dhoni says he will play for Chennai Super Kings in IPL 2023; Fans go ecstatic!
- Education SSC Junior Engineer 2020 Final Result Declared, Download SSC JE 2020 Final Results On ssc.nic.in
- Travel Best Camping Site Near Pune And Mumbai – Pawna Lake Camping, 1N/2D
The third dose of the AstraZeneca COVID-19 vaccine is effective against symptomatic disease and hospitalisation, offering protection comparable to a booster shot of the Pfizer preventive, according to a study conducted in the UK.
The yet-to-be peer-reviewed study, posted on the preprint repository medRxiv on May 1, assessed the effectiveness of the AstraZeneca (ChAdOx1-S) COVID-19 booster, and compared it with the protection offered by Pfizer (BNT162b2) booster shot.
The researchers from the UK Health Security Agency, London, estimated vaccine effectiveness by analysing data on all adults aged 18 years and above who were vaccinated with the AstraZeneca primary vaccine and either the same or the Pfizer booster vaccine.
A total of 43,171 individuals received an AstraZeneca booster dose, while 13,038,908 individuals received a Pfizer booster dose.
The results show that after 25 or more weeks since primary vaccination with AstraZeneca, vaccine effectiveness against symptomatic disease post-Omicron infection was 8.0 per cent and 19.5 per cent among individuals aged 40 to 64 years and 65 years and above, respectively.
One week after receiving the AstraZeneca booster, the vaccine effectiveness against symptomatic infection was 61.2 per cent among individuals aged 40 to 64 years, while that among Pfizer booster recipients was 58.2 per cent for the same age group.
However, 15 weeks or more after the booster dose, vaccine effectiveness reduced to 37.2 per cent for the AstraZeneca booster and 30.6 per cent for the Pfizer booster. The team observed comparable levels of protection against symptomatic infection among individuals aged 65 years and above.
"Protection against symptomatic disease in those aged 65 years and older peaked at 66.1 per cent and 68.5 per cent amongst those who received the ChAdOx1-S and BNT162b2 booster vaccines, respectively," the authors of the study noted. "Protection waned to 44.5 per cent and 54.1 per cent after 5-9 weeks," they said.
The study found that protection against hospitalisation following Omicron infection peaked at 82.3 after receiving an AstraZeneca booster, as compared to 90.9 per cent for those who received a Pfizer booster.
The research supports the use of the AstraZeneca booster for protection against severe disease with COVID-19 in settings that have not yet offered booster doses, the researchers said.
It suggests that those who received AstraZeneca as a booster in England do not require re-vaccination ahead of others, they said.
- wellnessDr Reddy's Lab To Approach Regulator For Sputnik Light As Universal Booster Dose
- wellnessHaven't Had Covid-19 Yet? It Could Be More Than Just Luck
- wellnessSome Short-Term Benefits Of Additional Booster Dose Of mRNA Vaccine In Health Workers: WHO
- wellnessWhy People With Lung Disorder Face Risk Of Severe Covid-19 Found
- wellnessOestrogen Treatment Linked With Reduced Covid Mortality: Study
- wellnessTrained Sniffer Dogs May Accurately Detect COVID Infected Airport Passengers: Study
- wellnessBiological E Ltd Reduces Price Of Its Covid-19 Vaccine Corbevax To Rs 250 Per Dose
- wellnessSouth Africa In New Surge Of COVID-19 From Versions Of Omicron
- wellnessCovid-19 Virus Is Not Viable On Cash Banknotes, Study Finds
- wellnessNew Computer Model Can Help Assess Covid-19 Impact, Progression In Detail
- wellnessActive Covid-19 Cases In The Country Dip To 18,604
- diabetesDiabetes Almost Doubles The Risk Of Death From Covid-19: Study